FindTrial
Sign In

Extended PET scanning in patients with incurable hepatocellular carcinoma (HCC) treated with sorafenib.

Extended PET scanning in patients with incurable hepatocellular carcinoma (HCC) treated with sorafenib. - Extended PET scanning in incurable hepatocellular carcinoma

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON32355
Enrollment
10
Registered
2008-01-29
Start date
2007-12-01
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma liver cancer

Interventions

None listed

Sponsors

Universitair Medisch Centrum Groningen
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Incurable HCC, 2. Treatment with sorafenib is/will be started 3. At least 18 years of age 4. A life expectancy of at least 3 month 5. Signed written informed consent 6. Able to comply with the protocol 7. Tumor response confirmed by CT-scan after 3 month (t=0 is start the sorafenib)

Exclusion criteria

Exclusion criteria: 1. Dementia or altered mental status that would prohibit giving of informed consent 2. Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
An initial negative PET will change in a positive scan—

Secondary

MeasureTime frame
Relation initial PET negative scan and survival benefit—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)